EUCTR2020-005735-79-FR进行中（未招募）1 期
Treatment with Tucatinib in addition to Pertuzumab and Trastuzumab in patients with HER2-positive metastatic breast cancer after local therapy of isolated brain progression - InTTercePT
ICANCER0 个研究点目标入组 55 人开始时间: 2021年6月25日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 55
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Male or female, Age =18;
- •2.Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0-1;
- •3.Histologically confirmed HER2 positive breast cancer, with HER2 positive defined by in situ hybridization (ISH), immunohistochemistry (IHC), or fluorescence in situ hybridization (FISH) methodology;
- •4.Documented isolated brain progression (defined as new or progressive brain metastases with stable or responding systemic disease) under pertuzumab and trastuzumab treatment (with or without taxane) for metastatic disease (There is no limit to the number and size of brain metastasis);
- •5.Complete local treatment of brain progression (Surgery and/or radiation therapy) should have been completed no more than 12 weeks before inclusion and there is no clinical indication for immediate re-treatment with local therapy in the opinion of the investigator;
- •6.Able to undergo MRI scanning of the brain;
- •7.Normal renal function: creatinine <1.5 x upper limit of normal (ULN);
- •8.Adequate liver function: total bilirubin =1.5 ULN (unless documented Gilbert’s syndrome); AST and ALT =2.5 ULN (=5 ULN in the presence of liver metastases);
- •9.Normal hematological function: ANC =1.5 x 109/L; platelets count =100 x 109/L; and hemoglobin =9.0 g/dL;
- •10.Adequate cardiac functions, including:
- •12 Lead electrocardiograms (ECG) with normal tracing or non-clinically significant changes that do not require medical intervention
- •QTc interval =480 msec (mean of replicate values, correction per institutional standard)
- •Left ventricular ejection fraction (LVEF) =50%
- •No history of Torsades de Pointes or other symptomatic QTc abnormality
- •11.Stable dose of steroids at the time of enrolment;
- •12.Women of childbearing potential must have a negative pregnancy test (blood or urine test) within 14 days prior to inclusion;
- •13.Woman of childbearing potential and male patients must agree to use adequate contraception for the duration of trial participation and up to 7 months after completing treatment/therapy (association of trastuzumab, pertuzumab +/- tucatinib). Hormonal contraceptives such as birth control pills, patches, implants, or injections are not allowed in patients who are hormone receptor positive;
- •14.Patient must have signed a written informed consent form prior to any trial specific procedures. When the patient is physically unable to give their written consent, a trusted person of their choice, independent from the investigator or the sponsor, can confirm in writing the patient’s consent;
- •15.Patients affiliated to the social security system (or equivalent);
- •16.Patient must be willing and able to comply with the protocol for the duration of the trial including scheduled visits, treatment plan, laboratory tests, and examinations including follow-up.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 37
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 18
排除标准
- •1.Radiologic extra-cranial progression under pertuzumab and trastuzumab treatment, at the time of enrolment. The systemic disease must be stable or responding at the time of enrolment;
- •2.Proven leptomeningeal disease;
- •3.Any progressive brain lesion between the brain local treatment completion and the enrolment;
- •4.Poorly controlled seizures (more than 1/week);
- •5.Clinically significant cardiopulmonary disease;
- •6.Used of a strong cytochrome P450 (CYP)2C8 inhibitor within 5 half-lives of the inhibitor, or use of a strong CYP3A4 or CYP2C8 inducer within 5 days prior to first dose of study treatment. Use of sensitive CYP3A substrates should be avoided one week before enrollment and during study treatment
- •7.Previous treatment with a tyrosine kinase inhibitor;
- •8.Carriers of Hepatitis B or Hepatitis C or have other known chronic liver disease;
- •9.Positive for human immunodeficiency virus (HIV);
- •10.Known prior severe hypersensitivity to tucatinib or compounds chemically or/and biologically similar or any component in its formulation;
- •11.History of any other cancer (except non-melanoma skin cancer or carcinoma in-situ of the cervix) unless the patient has been in remission and off all other cancer therapy for at least 3 years;
- •12.Pregnant women or women who are breast-feeding;
- •13.Inability to swallow tablets or significant gastrointestinal disease which would preclude the adequate oral absorption of medications;
- •14.Person deprived of their liberty or under protective custody or guardianship or unable to give informed consent;
- •15.Participation in another therapeutic trial within the 30 days prior to tucatinib treatment initiation.
研究者
相似试验
招募中
1 期
Multi-drug treatment for breast cancer patients with brain metastasesCTIS2024-510703-11-00nicancer55
尚未招募
不适用
eoadjuvant trastuzumab, pertuzumab and tucatinib without chemotherapy in HER2-positive breast cancer: the TRAIN-4 studyBreast cancerNL-OMON53609Antoni van Leeuwenhoek Ziekenhuis30
已完成
2 期
Phase II Trial of Pertuzumab plus Trastuzumab plus Docetaxel for HER2-Positive Metastatic Breast Cancer that Progressed During Prior Trastuzumab TherapyHER2-Positive Metastatic Breast CancerJPRN-UMIN000012452Chiba Youth Breast Oncology Research Group (CYBORG)35
招募中
2 期
A Phase II study of pertuzumab+trastuzumab+capecitabine in Patients with taxans and trastuzumab refractory for advanced or recurrent breast cancerHER2-positive metastatic breast cancerJPRN-UMIN000012030Saitama Breast Cancer Clinical Study Group30
进行中（未招募）
1 期
Tucatinib in combination with Oral Etoposide (VP16) and Trastuzumab in Patients with metastatic HER2+ Breast cancer (TUC-TOC)CTIS2022-500743-20-00Institut Curie66